Mid-Stage Trial Shows Shionogi’s Peramivir Equal to Tamiflu, GSK’s Relenza
This article was originally published in PharmAsia News
A Phase II trial in Japan has shown the drug peramivir developed by Japan's Shionogi and U.S.-based BioCryst effective in reducing flu symptoms. Researchers said the drug appears to be as effective as Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir), the top drugs now used to treat influenza. Peramivir was tested against the other drugs in two different doses, using the same test the other drugs had faced. The head researcher said Shionogi's drug should be a good option for flu patients. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.